Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan

International Journal of Urology

Volumn 19, Issue 4, 2012, Pages 284-295

  Wada, Yoshihiro ^a   Takahashi, Wataru ^a   Kawano, Yoshiaki ^a   Eto, Masatoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Angiogenesis inhibitors; Immunotherapy; Mammalian target of rapamycin inhibitors; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CALCIUM; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; HEMOGLOBIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANGINA PECTORIS; ANOREXIA; ASTHENIA; CALCIUM BLOOD LEVEL; CANCER RISK; CLEAR CELL CARCINOMA; DIARRHEA; DRUG ERUPTION; FATIGUE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; INFECTION; JAPAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; METASTASIS; METASTATIC RENAL CELL CARCINOMA; NAUSEA; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; JAPAN; KIDNEY NEOPLASMS;

EID: 84858966564     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.02962.x     Document Type: Review

References (65)

1. Motzer RJ, Mazumdar M, Bacik J etal. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-40.
2. Motzer RJ, Bacik J, Murphy BA etal. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
3. Heng DY, Xie W, Regan MM etal. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009; 27: 5794-9.
4. Naito S, Yamamoto N, Takayama T etal. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 2010; 57: 317-25.
5. Patil S, Figlin RA, Hutson TE etal. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 2011; 22: 295-300.
6. Heng DYC, Xie W, Regan MM etal. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J. Clin. Oncol. 2010; 27: 5794-9.
7. Desai J, Yassa L, Marqusee E etal. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 2006; 145: 660-4.
8. Fujioka T, Obara W, Committee for Establishment of the Clinical Practice Guidelines for the Management of Renal Cell Carcinoma, Japanese Urological Association. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary - JUA 2007 Edition). Int. J. Urol. 2009; 16: 339-53.
9. Coppin C, Porzsolt F, Awa A etal. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005; (1): CD001425.
10. Ito N, Eto M, Nakamura E etal. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2007; 25: 2785-91.
11. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 1993; 20: 283-95.
12. Ljungberg B, Cowan NC, Hanbury DC etal. European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 2010; 58: 398-406.
13. Fyfe G, Fisher RI, Rosenberg SA etal. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 1995; 13: 688-96.
14. Akaza H, Tsukamoto T, Onishi T etal. A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int. J. Clin. Oncol. 2006; 11: 434-40.
15. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 2007; 57: 112-25.
16. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer 2006; 94: 614-9.
17. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24: 5601-8.
18. Latif F, Tory K, Gnarra J etal. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-20.
19. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J. Urol. 2003; 170: 2163-72.
20. Zbar B, Klausner R, Linehan WM. Studying cancer families to identify kidney cancer genes. Annu. Rev. Med. 2003; 54: 217-33.
21. Banks RE, Tirukonda P, Taylor C etal. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006; 66: 2000-11.
22. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 1975; 28: 727-32.
23. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 1977; 55: 48-51.
24. Brown EJ, Albers MW, Shin TB etal. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
25. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 1981; 8: 63-87.
26. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22989) against transplanted tumors. J. Antibiot. (Tokyo) 1984; 37: 1231-7.
27. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861-72; discussion 873-4.
28. Thomas GV, Tran C, Mellinghoff IK etal. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006; 12: 122-7.
29. Brenner W, Färber G, Herget T etal. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 2002; 99: 53-7.
30. Hara S, Oya M, Mizuno R etal. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 2005; 16: 928-33.
31. Escudier B, Szczylik C, Hutson TE etal. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 1280-9.
32. Escudier B, Eisen T, Stadler WM etal. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
33. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
34. Motzer RJ, Hutson TE, Tomczak P etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 3584-90.
35. Hudes G, Carducci M, Tomczak P etal. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
36. Motzer RJ, Escudier B, Oudard S etal. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
37. Thomas AA, Rini BI, Lane BR etal. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 2009; 181: 518-23; discussion 523.
38. Akaza H, Tsukamoto T, Murai M etal. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn. J. Clin. Oncol. 2007; 37: 755-62.
39. Uemura H, Shinohara N, Yuasa T etal. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn. J. Clin. Oncol. 2010; 40: 194-202.
40. Bukowski RM, Stadler WM, McDermott DF etal. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010; 78: 340-7.
41. Gore ME, Szczylik C, Porta C etal. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-63.
42. Gary Hudes MD, Michael Carducci MD, PiotrTomczak MD etal. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
43. Amato RJ, Jac J, Giessinger S etal. Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438-46.
44. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198-220.
45. Sablin MP, Negrier S, Ravaud A etal. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 2009; 182: 29-34; discussion 34.
46. Dudek AZ, Zolnierek J, Dham A etal. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-7.
47. Di Lorenzo G, Cartenì G, Autorino R etal. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol. 2009; 27: 4469-74.
48. Atzpodien J, Kirchner H, Hänninen EL etal. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer 1993; 29A (Suppl 5): S6-8.
49. Gore ME, Griffin CL, Hancock B etal. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375: 641-8.
50. Akaza H, Kawai K, Tsukamoto T etal. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn. J. Clin. Oncol. 2010; 40: 684-9.
51. Rini BI, Halabi S, Rosenberg JE etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008; 26: 5422-8.
52. Escudier B, Pluzanska A, Koralewski P etal. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
53. Bukowski RM, Kabbinavar FF, Figlin RA etal. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 2007; 25: 4536-41.
54. Jonasch E, Corn P, Pagliaro LC etal. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 57-65.
55. Escudier B, Lassau N, Angevin E etal. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 2007; 13: 1801-9.
56. Gollob JA, Rathmell WK, Richmond TM etal. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 2007; 25: 3288-95.
57. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 2007; 13: 764s-769s.
58. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 2004; 10: 6290S-6295S.
59. Hainsworth JD, Sosman JA, Spigel DR etal. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 2005; 23: 7889-96.
60. Hainsworth JD, Spigel DR, Burris HA III etal. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 2010; 28: 2131-6.
61. Dutcher JP, de Souza P, McDermott D etal. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 2009; 26: 202-9.
62. Choueiri TK, Plantade A, Elson P etal. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008; 26: 127-31.
63. Stadler WM, Figlin RA, Ernstoff MS. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). ASCO abstract #5036, 2007.
64. Oudard S, Banu E, Vieillefond A etal. GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J. Urol. 2007; 177: 1698-702.
65. Nanus DM, Garino A, Milowsky MI etal. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101: 1545-51.